Navigation Links
Irritable Bowel Syndrome Takes Center Stage at Yakult's 17th Intestinal Flora Symposium
Date:11/3/2008

- Probiotics may offer sufferers non-drug option for symptom relief -

TOKYO, Nov. 3 /PRNewswire/ -- Last Friday, the 17th Annual Symposium on Intestinal Flora at Yakult World Headquarters Hall in Tokyo gathered physicians, researchers and company associates from 19 countries, including the U.S. This year's theme, "Intestinal Microbiota and Functional Gastrointestinal Disorders" focused on brain-gut interactions and Irritable Bowel Syndrome, which is believed to be the "entry illness" that leads to various digestive diseases.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070911/YAKULTLOGO)

IBS affects up to 25% of the world population and roughly one in five Americans. It is caused by an inflammatory reaction in the intestines, often triggered by stress, and results in a change to gut microflora. These mechanisms and other new discoveries about the brain-gut relationship were presented to a packed room of more than 500 attendees.

"Probiotics show promise for manipulating gut microflora," predicated Stephen M. Collins of McMaster University, Canada concluding his presentation, 'The Influence of Commensally Bacteria on the Gut-Brain Axis.' Probiotics are appealing for IBS sufferers since they are not drugs, have no side effects and can help maintain intestinal balance.

Other presentations included: "Stress and brain-gut interactions in IBS," by Shin Fukudo (Tohoku University, Japan); "Intestinal inflammation and motor function," by Hiroshi Ozaki (University of Tokyo); "Effect of stress-related peptides on colonic motility," by Shigeru Yamato (International Medical Center of Japan, Konodai Hospital); "Probiotics and IBS," by Eamonn M. Quigley (Cork University, Ireland); "Stress and intestinal microbiota," by Michael T. Bailey (Ohio State University); and "IBS: medicine and probiotics," by Mitsuhisa Kawai (Yakult Central Institute for Microbiological Research, Japan).

Yakult Honsha Ltd., Co. developed the symposium in 1992 when probiotics research gripped doctors and scientists abroad. Since then, it has become one of the world's most prominent forums discussing the hottest research and advancements in the probiotics field. The symposium is free and open to the public every year; in Japan no registration is required. Interested participants in the U.S. can reserve a seat for future symposia by contacting Yakult USA Inc. at science@yakultusa.com.

Founded by Dr. Minora Shirota, Yakult Honsha Ltd., Co. was established in Japan in 1955 and is regarded as the world's pioneer of probiotics. The company produces Yakult, the original probiotic dairy drink containing the exclusive strain Lactobacillus casei Shirota. Scientists all over the world continue to confirm and expand knowledge regarding the health benefits of Yakult and probiotics. Yakult U.S.A. Inc. is a subsidiary of Tokyo-based Yakult Honsha Co., Ltd. and is headquartered in Torrance, CA. It supports Yakult's activities in the United States and Canada. For more information, visit http://www.yakultusa.com.


'/>"/>
SOURCE Yakult U.S.A. Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Allergic disease linked to irritable bowel syndrome
2. Abuse history affects pain regulation in women with irritable bowel syndrome
3. Harnessing the Mind to Manage Irritable Bowel Syndrome
4. Allergy Disorders Linked With Irritable Bowel Syndrome
5. Antidepressant found to alleviate symptoms of irritable bowel syndrome in adolescents
6. AMITIZA 8 mcg now available to treat irritable bowel syndrome
7. ReachMD XM 157 Announces Medical Information Feature on Irritable Bowel Syndrome, Its Treatments, and the Role of Probiotics
8. Elsevier announces new journal on inflammatory bowel diseases
9. C-diff infection 4 times more likely to kill patients with inflammatory bowel disease
10. Mesalamine linked to cancer protection for high risk inflammatory bowel disease patients
11. Threshold for bowel surgery may be too high, warn experts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... 2017 , ... The next Patient Care Academy at Kalamazoo Valley Community College ... complete the seven-week long Patient Care Academy are eligible to take the State of ... a CNA in Kalamazoo is $24,428.* , As a CNA, one is equipped for ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... Ten outstanding ... Union's Stars in the Classroom and will win a visit by a Houston Texans ... K-12 who are at least five years old can visit texanschecking.com/stars to nominate their ...
(Date:8/16/2017)... ... August 16, 2017 , ... In 1987, ... celebrate 30 years in business this year, and they’re marking the milestone by ... to serve their patients. , It stands to reason that, given the ...
(Date:8/16/2017)... ... August 16, 2017 , ... Maury Regional Health has announced ... draws. By broadly deploying AccuVein devices, Maury Regional Medical Center is making vein visualization ... out of a needle stick and more importantly, helps our staff members locate a ...
(Date:8/16/2017)... ... 16, 2017 , ... A global leader in the treatment of clubfoot, ... 29 Indian states—bringing the country one step closer to eliminating clubfoot as a lifelong ... is on track to enroll 10,000 children in the clubfoot treatment program in this ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... 2017 Insightin Health, provider of data-driven ... engagement, announced the selection of Michael Wood ... effective as of February 2017. In this role, Wood ... for our clients. Wood brings with him more ... business analytics within the healthcare industry. Wood formerly ...
(Date:8/7/2017)... (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced financial ... unless otherwise noted, are to the quarter ended June 30, ... 2017 Highlights include: Revenue of $1,126 ... Total prescriptions dispensed of 220,000, compared to 241,000 ... Gross profit per prescription dispensed of $371, ...
(Date:8/4/2017)... 3, 2017  Agragen, LLC, a ... the biopharmaceutical, nutraceutical, and aquacultural feed sectors, announces ... lead drug candidates, AGR131.  This drug is designed ... the blood of patients suffering from inflammatory conditions ... disease. Biological ...
Breaking Medicine Technology: